PARLIAMENTARY WRITTEN QUESTION
Tixagevimab/cilgavimab (12 May 2022)
Question Asked
Asked by:
Sir Alan Campbell (Labour)
Answer
The Department continues to examine the potential introduction of prophylaxis, which includes deployment and administration processes. On 17 March 2022, Evusheld was granted conditional marketing approval by the Medicines and Healthcare products Regulatory Agency. However, the approval highlighted uncertainty over the dose required for protection against the Omicron variants.
We have asked clinicians to advise on the most appropriate option for the National Health Service in line with all available data, the public health situation and other treatments available.
Answered by:
Maggie Throup (Conservative)
8 June 2022
Contains Parliamentary information licensed under the Open Parliament Licence v3.0.